GB201205752D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB201205752D0
GB201205752D0 GB201205752A GB201205752A GB201205752D0 GB 201205752 D0 GB201205752 D0 GB 201205752D0 GB 201205752 A GB201205752 A GB 201205752A GB 201205752 A GB201205752 A GB 201205752A GB 201205752 D0 GB201205752 D0 GB 201205752D0
Authority
GB
United Kingdom
Prior art keywords
hours
plasma concentration
mumu
alkyl
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201205752A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Priority to GB201205752A priority Critical patent/GB201205752D0/en
Publication of GB201205752D0 publication Critical patent/GB201205752D0/en
Priority to EP13714992.8A priority patent/EP2833865A1/en
Priority to US14/387,963 priority patent/US20150320762A1/en
Priority to PCT/GB2013/050816 priority patent/WO2013144632A1/en
Priority to JP2015502453A priority patent/JP2015514703A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB201205752A 2012-03-30 2012-03-30 Treatment Ceased GB201205752D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB201205752A GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment
EP13714992.8A EP2833865A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones
US14/387,963 US20150320762A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones
PCT/GB2013/050816 WO2013144632A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones
JP2015502453A JP2015514703A (ja) 2012-03-30 2013-03-28 ピリミドジアゼピノンを用いた増殖性疾患の治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201205752A GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment

Publications (1)

Publication Number Publication Date
GB201205752D0 true GB201205752D0 (en) 2012-05-16

Family

ID=46160090

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201205752A Ceased GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment

Country Status (5)

Country Link
US (1) US20150320762A1 (cg-RX-API-DMAC10.html)
EP (1) EP2833865A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015514703A (cg-RX-API-DMAC10.html)
GB (1) GB201205752D0 (cg-RX-API-DMAC10.html)
WO (1) WO2013144632A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
ES3036562T3 (en) * 2019-08-16 2025-09-22 Cyclacel Pharmaceuticals Inc Crystalline forms of pyrimidino diazepine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0718608D0 (en) 2007-09-24 2007-10-31 Tyco Electronics Raychem Nv Cable termination
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物

Also Published As

Publication number Publication date
US20150320762A1 (en) 2015-11-12
EP2833865A1 (en) 2015-02-11
WO2013144632A1 (en) 2013-10-03
JP2015514703A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
UA110259C2 (uk) Похідні піролопіримідину і пурину
EA201690752A1 (ru) Ингибиторы g12c kras
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX381326B (es) Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
MX337440B (es) Antagonistas de trpv4.
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
EA201270778A1 (ru) Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
EA201301025A1 (ru) Преодоление устойчивости к ингибиторам пути erbb
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
EA201790713A1 (ru) N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
EA201270755A1 (ru) Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
RU2009103810A (ru) Новые соединения
RU2015150120A (ru) Соединение дикарбоновой кислоты
MX385276B (es) Tratamiento para la enfermedad de parkinson
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)